Clinical Study

Ppmi 2.0 Clinical -Establishing A Deeply Phenotyped Pd Cohort

Posted Date: Apr 30, 2021

  • Investigator: Alberto Espay
  • Specialties: Movement Disorders, Neurology, Parkinson's Disease
  • Type of Study: Observational/Survey

The Parkinson Progression Marker Initiative 2.0 (PPMI 2.0) is a longitudinal, observational, multi-center natural history study to assess progression of clinical features, digital outcomes, and imaging, biologic and genetic markers of Parkinson's disease (PD) progression in study participants with manifest PD, prodromal PD, and healthy controls. The overall goal of PPMI 2.0 is to identify markers of disease progression for use in clinical trials of therapies to reduce progression of PD disability.




Parkinson's Disease, Neurology, Espay

For More Information:

Christina Gruenwald

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.